SCHEMBL4481484

SCHEMBL4481484

CN(C)CC(=O)N(C)c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2cccc(CC(=O)O)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 2/20 0.36
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 2/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
MDM2 Q00987 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PLK1 P53350 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
FFAR1 O14842 1/20 0.32
TP53 P04637 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481485 1.00 SENP1 (0.36) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4504395 0.93 PLK1 (0.35) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4504399 0.93 PLK1 (0.35) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4499842 0.92 PLK1 (0.37) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL223725 0.92 PLK1 (0.38) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL223724 0.92 PLK1 (0.38) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4499846 0.92 PLK1 (0.37) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4501993 0.92 PLK1 (0.39) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4501991 0.92 PLK1 (0.39) SENP1ALDH1A1NPC1MAPTHPGD
SCHEMBL4485968 0.91 KDM4E (0.37) NPC1MAPTNR1H4KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR SENP1 3761/4885ALDH1A1 2036/4885NPC1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.